Mike and I recently had the opportunity to regroup with Jody Vance on Equity Guru for a business update on a range of our current advancements.

There is extensive discussion about our work with Ivermectin – including our upcoming advanced BSL-4 lab COVID-19 clearance trial and its significant therapeutic implications globally.  And we take a few minutes to run through our current work on cold chain, our dose sparing adjuvant, mucosal immunity and more.

You can watch our interview with Jody Vance here:

INTERVIEW LINK - https://www.youtube.com/watch?v=Pvoe1v1Lr_Y&feature=youtu.be
 

Despite all of the unimaginable devastation we have seen with the COVID-19 outbreak, most health professionals would agree that this pandemic is extremely mild based on what is certain to follow.  There will be future pandemics that will move faster with higher mortality rates and MVMD is doing work that will not only help now, but define how future pandemics are managed.  That is why we are moving so fast in everything we do.

We continue to be inspired and united in our mission to truly redefine what is possible in the global animal and human health landscape.

Thanks for your ongoing support of Mountain Valley MD!
 

Regards,
 
Dennis